More about

Leiden University Medical Center

News
September 19, 2022
2 min read
Save

Pre-arthritis methotrexate use improves RA course, fails to prevent clinical arthritis

Pre-arthritis methotrexate use improves RA course, fails to prevent clinical arthritis

Methotrexate use at the pre-arthritis stage of symptoms and subclinical inflammation fails to prevent clinical arthritis, but does improve symptoms and MRI-detected inflammation vs. placebo, according to data published in The Lancet.

News
September 08, 2022
2 min read
Save

Most women who take anticoagulants for blood clots experience abnormal menstrual bleeding

Most women who take anticoagulants for blood clots experience abnormal menstrual bleeding

Two-thirds of women of child-bearing age who began taking anticoagulants for acute venous thromboembolism had abnormally heavy menstrual bleeding in the months that followed therapy initiation, according to data from a prospective study.

News
August 31, 2022
2 min read
Save

Upadacitinib efficacious in patients with ankylosing spondylitis refractory to biologics

Upadacitinib efficacious in patients with ankylosing spondylitis refractory to biologics

Upadacitinib is efficacious over 14 weeks in patients with ankylosing spondylitis who mounted poor responses to biologic disease-modifying antirheumatic drugs, according to data published in the Annals of the Rheumatic Diseases.

News
June 28, 2022
10 min read
Save

Novel approaches highlight potential of cell therapy for a wider array of cancers

Novel approaches highlight potential of cell therapy for a wider array of cancers

The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.

News
January 05, 2022
2 min read
Save

Unvalidated patient-reported outcome measures limit acromegaly, GH studies

Unvalidated patient-reported outcome measures limit acromegaly, GH studies

One-third of acromegaly and growth hormone deficiency studies report discrepancies between patient-reported outcomes and biochemical outcomes, with many using unvalidated and poorly reported outcome measures, data from a meta-analysis show.

News
October 08, 2021
2 min read
Save

Oral baricitinib maintains lower radiographic progression than csDMARD, placebo in RA

Oral baricitinib maintains lower radiographic progression than csDMARD, placebo in RA

Oral baricitinib is linked to lower levels of 5-year radiographic progression than first-line conventional, synthetic disease-modifying antirheumatic drugs or placebo in rheumatoid arthritis, according to data published in The Journal of Rheumatology.

News
September 09, 2021
2 min read
Save

Perimenstrual migraine attack duration affects recurrence risk, triptan use

Perimenstrual migraine attack duration affects recurrence risk, triptan use

Longer duration of perimenstrual migraine attacks among women with menstrual-related migraine appeared linked to increased recurrence risk and triptan use, according to results of a prospective study published in Neurology.

News
September 07, 2021
2 min read
Save

No association found between subclinical thyroid dysfunction and cognitive decline

No association found between subclinical thyroid dysfunction and cognitive decline

Subclinical hypothyroidism and hyperthyroidism are not associated with cognitive function, cognitive decline or dementia, according to an analysis of data of more than 74,000 people from 23 cohorts published in JAMA Internal Medicine.

News
July 19, 2021
2 min read
Save

Physical therapy referrals for systemic sclerosis underused in primary care

Physical therapy referrals for systemic sclerosis underused in primary care

There is a “large variability” in the use of physical therapy for systemic sclerosis, and patients who do receive it are rarely treated for hand or oral dysfunction, according to data published in Arthritis Care & Research.

News
June 07, 2021
2 min read
Save

Ixekizumab demonstrates low radiographic progression in axial SpA at 2 years

Ixekizumab demonstrates low radiographic progression in axial SpA at 2 years

Most patients with active, radiographic axial spondyloarthritis who receive ixekizumab for 2 years show no radiographic disease progression, with low mean progression overall, according to a poster presentation at the EULAR 2021 Congress.

View more